Analysts predict that several Chinese biotechnology firms may successfully market their own branded medications in Europe and the US within the next decade. This projection is fueled by a rise in outlicensing agreements, where Chinese companies grant overseas partners rights to develop and sell their early-stage drugs. The US market is particularly attractive due to its high drug prices and significant contribution to global pharmaceutical profits. AI
RANK_REASON Article discusses analyst predictions and market trends rather than a specific event.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
